Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),
Jeffrey S. Wasser(Community Cancer Center), Richard Lizambri(Amgen (United States)), Marc Michel(Université Paris-Est Créteil), Jean‐François Viallard(Université de Bordeaux), Xuena Wang(Tianjin University of Traditional Chinese Medicine), Romeo A. Mandanas, Ingrid Pabinger(Medical University of Vienna), Ralph V. Boccia(Center for Cancer and Blood Disorders), Roger M. Lyons(Hematology Oncology Associates)
Cited by 1
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Increased fetal loss in women with heritable thrombophilia
|The Lancet|1996|677
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425